<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;N03A&quot;,&quot;href&quot;:&quot;atc/N03A.md&quot;},{&quot;label&quot;:&quot;phenobarbital&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;Phenobarbital_Stoschus2025_reference&quot;,&quot;label&quot;:&quot;Stoschus_2025_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_phenobarbital/Phenobarbital_Stoschus2025_reference.md&quot;,&quot;status&quot;:&quot;reviewed \u2014 candidate&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Phenobarbital_TeixeiradaSilva2022_reference&quot;,&quot;label&quot;:&quot;Teixeira-da-Silva_2022_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_phenobarbital/Phenobarbital_TeixeiradaSilva2022_reference.md&quot;,&quot;status&quot;:&quot;reviewed \u2014 candidate&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Phenobarbital_Yalcin2022_reference&quot;,&quot;label&quot;:&quot;Yalcin_2022_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_phenobarbital/Phenobarbital_Yalcin2022_reference.md&quot;,&quot;status&quot;:&quot;reviewed \u2014 candidate&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false}]"></div>

# phenobarbital

- **generic name:** phenobarbital
- **ATC codes:** `N03AA02`
- **DrugBank:** [DB01174](https://go.drugbank.com/drugs/DB01174) · **PubChem:** [CID 4763](https://pubchem.ncbi.nlm.nih.gov/compound/4763)
- **molar mass:** 232.2353 g/mol (C12H12N2O3) — DrugBank
- **groups:** approved, investigational

## About

Phenobarbital is a barbiturate anticonvulsant used to treat epilepsy and seizures, including status epilepticus and neonatal seizures, and has also been used for sleep problems and anxiety. It remains in use, is listed as an essential medicine by the WHO, and is approved, though today it is used relatively sparingly for epilepsy.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q407241](https://www.wikidata.org/wiki/Q407241) and the WHO ATC classification; not checked by a person.</small>

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-10 02:01 | 23:49 | 3/0/0 | 0/1/0 | 2/0/3 | 217,501/13,479 | ollama / qwen3.8:27b-mtp-q8_0 | 23 | 4/18 | 21/2 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">reviewed — candidate</span> | [Stoschus_2025_reference](drugs/drug_phenobarbital/Phenobarbital_Stoschus2025_reference.md) | ▶ model + simulator | 1-compartment, oral | 3 | Stoschus M et al., Optimizing phenobarbital dosing in crit…, Epilepsia (2025) | [10.1111/epi.18517](https://doi.org/10.1111/epi.18517) |
| <span class="pk-badge pk-badge--green">reviewed — candidate</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (partly confirmed, agreement 0.429). The first reading is what the record holds.">cross-check: partial</span> | [Teixeira-da-Silva_2022_reference](drugs/drug_phenobarbital/Phenobarbital_TeixeiradaSilva2022_reference.md) | ▶ model + simulator | 1-compartment, oral | 3 | Teixeira-da-Silva P et al., Population Pharmacokinetics of Valproic…, Pharmaceutics (2022) | [10.3390/pharmaceutics14040811](https://doi.org/10.3390/pharmaceutics14040811) |
| <span class="pk-badge pk-badge--green">reviewed — candidate</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.167). The first reading is what the record holds.">cross-check: disputed</span> | [Yalcin_2022_reference](drugs/drug_phenobarbital/Phenobarbital_Yalcin2022_reference.md) | ▶ model + simulator | 1-compartment, IV | 2 | Yalcin N et al., Population pharmacokinetics in critical…, BMJ paediatrics open (2022) | [10.1136/bmjpo-2022-001512](https://doi.org/10.1136/bmjpo-2022-001512) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--red">rejected</span> | [Lee_2019_ETCO2](drugs/drug_phenobarbital/pd_Lee_2019_ETCO2.md) | end-tidal carbon dioxide ← respiratory rate · direct sigmoid Emax (Hill) effect | — | Lee JH et al., A pharmacodynamic model of respiratory…, Acta pharmacologica Sinica (2019) | [10.1038/s41401-018-0156-x](https://doi.org/10.1038/s41401-018-0156-x) |

## Pharmacogenomics (PGx)

| status | gene | affects | mechanism | detail | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--neutral" title="a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.">safety allele</span> | **CYP2C9** | `safety` — adverse-reaction risk (HLA / safety allele) — no parameter shift | safety_allele | [Saruwatari_2010](drugs/drug_phenobarbital/pgx_Saruwatari_2010_CYP2C9_safety.md) | Saruwatari J et al., Update on the Genetic Polymorphisms of…, Pharmaceuticals (Basel, Swi… (2010) | [10.3390/ph3082709](https://doi.org/10.3390/ph3082709) |
| <span class="pk-badge pk-badge--neutral" title="a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.">safety allele</span> | **GST** | `safety` — adverse-reaction risk (HLA / safety allele) — no parameter shift | safety_allele | [Saruwatari_2010](drugs/drug_phenobarbital/pgx_Saruwatari_2010_GST_safety.md) | Saruwatari J et al., Update on the Genetic Polymorphisms of…, Pharmaceuticals (Basel, Swi… (2010) | [10.3390/ph3082709](https://doi.org/10.3390/ph3082709) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> | **CYP2C19** | `Q27` · CL/F | metabolism | [Saruwatari_2010](drugs/drug_phenobarbital/pgx_Saruwatari_2010_CYP2C19_Q27.md) | Saruwatari J et al., Update on the Genetic Polymorphisms of…, Pharmaceuticals (Basel, Swi… (2010) | [10.3390/ph3082709](https://doi.org/10.3390/ph3082709) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> | **EPHX1** | `Q27` · CL/F | metabolism | [Saruwatari_2010](drugs/drug_phenobarbital/pgx_Saruwatari_2010_EPHX1_Q27.md) | Saruwatari J et al., Update on the Genetic Polymorphisms of…, Pharmaceuticals (Basel, Swi… (2010) | [10.3390/ph3082709](https://doi.org/10.3390/ph3082709) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> | **UGT2B7** | `Q27` · CL/F | metabolism | [Saruwatari_2010](drugs/drug_phenobarbital/pgx_Saruwatari_2010_UGT2B7_Q27.md) | Saruwatari J et al., Update on the Genetic Polymorphisms of…, Pharmaceuticals (Basel, Swi… (2010) | [10.3390/ph3082709](https://doi.org/10.3390/ph3082709) |

<details class="pk-legend"><summary>What the PGx badges mean — evidence, and whether a model runs</summary><table><tbody><tr><td><span class="pk-badge pk-badge--green">quantitative</span></td><td>the paper gives the effect of each phenotype (or genotype) on a named model parameter — a θ per category.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">qualitative</span></td><td>the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">guideline estimate</span></td><td>the effect comes from a CPIC / DPWG dosing guideline, not from this paper's numbers.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">safety allele</span></td><td>a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>the extraction is incomplete or inconsistent.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted.</td></tr><tr><td><span class="pk-badge pk-badge--green">▶ simulatable</span></td><td>the paper's popPK model runs per phenotype in the browser (Simulation tab); its PGx Modelica model is under Models.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">model only</span></td><td>a PGx Modelica model exists but has no in-browser simulator.</td></tr></tbody></table></details>

<details class="legend">
<summary>What the PGx columns mean</summary>
<table><thead><tr><th>column</th><th>what it holds</th></tr></thead><tbody><tr><td><code>gene</code></td><td>the gene whose variants the record is about. One record per gene, so a paper reporting several genes appears on several rows.</td></tr><tr><td><code>affects</code></td><td>the PK or PD parameter the genotype SHIFTS, as an ontology Q-code plus its name — Q22 = clearance, Q27 = CL/F (apparent clearance), Q32 = Cmax, Q88 = AUC, Q40 = Fab, Q321 = EC50, Q322 = IC50, Q305 = kfm. The record's per-phenotype theta is a multiplier ON that parameter: a poor-metaboliser theta shifts this value, it does not supply one. Two values are NOT parameters — Q100 (NIL) is an association or risk finding with no parameter target, and `safety` is an adverse-reaction risk such as an HLA allele. A PA… id instead of a Q-code marks a record derived from a ClinPGx/PharmGKB guideline lookup rather than read out of the paper.</td></tr><tr><td><code>mechanism</code></td><td>how the gene acts: metabolism, transport, target, formation, safety_allele, or unknown.</td></tr><tr><td><code>detail</code></td><td>the paper stem, linking to the full record page.</td></tr><tr><th colspan="2" style="text-align:left;padding-top:10px">placeholders</th></tr><tr><td><code>not captured</code></td><td>the field is absent from the KB artifact — nothing was recorded. This is NOT the same as zero or empty: the value is unknown, not measured to be nothing.</td></tr><tr><td><code>—</code></td><td>deliberately not shown: the column does not apply to this row.</td></tr><tr><td><code>not verified</code></td><td>the record is not in an accepted state (see the badge and the note above the table); the numbers are shown as extracted, not endorsed.</td></tr></tbody></table>
</details>

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=phenobarbital) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | blood-brain barrier | `ABCB1` inducer/substrate | DrugBank actor |
| absorption | kidney | `ABCB1` inducer/substrate | DrugBank actor |
| absorption | liver | `ABCB1` inducer/substrate | DrugBank actor |
| absorption | placenta | `ABCB1` inducer/substrate | DrugBank actor |
| absorption | small intestine | `ABCB1` inducer/substrate | DrugBank actor |
| absorption | testis | `ABCB1` inducer/substrate | DrugBank actor |
| distribution | blood-brain barrier | `ABCC1` inducer | DrugBank actor |
| distribution | lung | `ABCC1` inducer | DrugBank actor |
| metabolism | kidney | `CYP3A5` inducer, `UGT2B7` inducer/metabolism | DrugBank actor |
| metabolism | liver | `CYP1A2` inducer, `CYP2A6` inducer, `CYP2B6` inducer, `CYP2C19` inducer/metabolism/substrate, `CYP2C8` inducer, `CYP2C9` inducer/safety_allele/substrate, `CYP2E1` inducer/substrate, `CYP3A4` inducer, `CYP3A5` inducer, `CYP3A7` inducer, `EPHX1` metabolism, `UGT1A1` inducer, `UGT2B7` inducer/metabolism | DrugBank actor |
| metabolism | lung | `CYP1A1` inducer | DrugBank actor |
| metabolism | small intestine | `CYP1A1` inducer, `CYP3A4` inducer, `CYP3A5` inducer, `UGT1A1` inducer, `UGT2B7` inducer/metabolism | DrugBank actor |
| excretion | kidney | `ABCC2` inducer | DrugBank actor |
| excretion | liver | `ABCB11` inducer, `ABCC2` inducer, `ABCC3` inducer | DrugBank actor |
| excretion | small intestine | `ABCC2` inducer, `ABCC3` inducer | DrugBank actor |

<sub>Actors without a tissue in the table: CHRNA4 (target), CHRNA7 (target), CYP2C18 (substrate), CYP4B1 (inducer), GABRA1 (potentiator), GRIA2 (target), GRIK2 (target), GRIN1 (target), GST (safety_allele), NR1I2 (activator), SLCO2A1 (inducer).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 1038 matched, 88 returned
- **screened:** 2  ·  **relevant:** 2
- **records:** 3  ·  extracted 3  ·  needs_review 0  ·  rejected 0  ·  stale 0
- **scholar-agent fallback query used:** not captured

## Full text wanted

_19 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Dingemanse_1989.pdf` | Dingemanse J et al., Pharmacokinetic modeling of the anticon…, The Journal of pharmacology… (1989) | popPK | 10 | not captured | [2724142](https://pubmed.ncbi.nlm.nih.gov/2724142) | The title confirms a pharmacokinetic modeling study of phenobarbital in rats, but the provided evidence contains no numeric parameter values. |
| `Moffett_2018.pdf` | Moffett BS et al., Phenobarbital population pharmacokineti…, Epilepsia (2018) | popPK | 10 | [10.1111/epi.14447](https://doi.org/10.1111/epi.14447) | [29897629](https://pubmed.ncbi.nlm.nih.gov/29897629) | The paper is a population PK study for phenobarbital, but the specific numeric parameter values (CL, V, Q, etc.) are not present in the provided text, which only describes the model structure and covariates. |
| `Teixeira-da-Silva_2020.pdf` | Teixeira-da-Silva P et al., Population pharmacokinetics of phenobar…, European journal of pharmac… (2020) | popPK | 10 | [10.1016/j.ejps.2020.105484](https://doi.org/10.1016/j.ejps.2020.105484) | [32707172](https://pubmed.ncbi.nlm.nih.gov/32707172) | The evidence explicitly provides the quantitative population pharmacokinetic model equation for phenobarbital clearance (CL/F) including specific numeric coefficients for BSA and drug interactions. |
| `Falcão_2012.pdf` | Falcão A et al., Pharmacokinetics, drug interactions and…, CNS drugs (2012) | pd | 5 | [10.2165/11596290-000000000-00000](https://doi.org/10.2165/11596290-000000000-00000) | [22171585](https://www.ncbi.nlm.nih.gov/pubmed/22171585) | metadata signals extractable PD data (exposure-response) |
| `Schoemaker_2016.pdf` | Schoemaker R et al., Brivaracetam Population Pharmacokinetic…, Journal of clinical pharmac… (2016) | pd | 5 | [10.1002/jcph.761](https://doi.org/10.1002/jcph.761) | [27146213](https://www.ncbi.nlm.nih.gov/pubmed/27146213) | metadata signals extractable PD data (Exposure-Response) |
| `Yang_2024.pdf` | Yang J et al., A pharmacokinetic-pharmacodynamic model…, Biotechnology & genetic eng… (2024) | pd | 5 | [10.1080/02648725.2023.2199232](https://doi.org/10.1080/02648725.2023.2199232) | [37018446](https://www.ncbi.nlm.nih.gov/pubmed/37018446) | metadata signals extractable PD data (pharmacodynamicmodel) |
| `Leppik_1979.pdf` | Leppik IE et al., Intravenous phenytoin and phenobarbital…, Epilepsia (1979) | pd | 4 | [10.1111/j.1528-1157.1979.tb04796.x](https://doi.org/10.1111/j.1528-1157.1979.tb04796.x) | [446431](https://www.ncbi.nlm.nih.gov/pubmed/446431) | metadata signals extractable PD data (EC50) |
| `Hagos_2019.pdf` | Hagos FT et al., Factors Contributing to Fentanyl Pharma…, Clinical pharmacokinetics (2019) | pgx | 8 | [10.1007/s40262-019-00773-1](https://doi.org/10.1007/s40262-019-00773-1) | [31168770](https://www.ncbi.nlm.nih.gov/pubmed/31168770) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Lee_2012.pdf` | Lee SM et al., Effects of cytochrome P450 (CYP)2C19 po…, Archives of disease in chil… (2012) | pgx | 8 | [10.1136/archdischild-2011-300538](https://doi.org/10.1136/archdischild-2011-300538) | [22331680](https://www.ncbi.nlm.nih.gov/pubmed/22331680) | metadata signals extractable PGX data (CYP2C19, PK/PD-context) |
| `Saruwatari_2014.pdf` | Saruwatari J et al., Effects of CYP2C19 and P450 oxidoreduct…, Therapeutic drug monitoring (2014) | pgx | 8 | [10.1097/FTD.0000000000000015](https://doi.org/10.1097/FTD.0000000000000015) | [24345815](https://www.ncbi.nlm.nih.gov/pubmed/24345815) | metadata signals extractable PGX data (CYP2C19, PK/PD-context) |
| `Van_2021.pdf` | Van Daele R et al., Concomitant use of isavuconazole and CY…, Mycoses (2021) | pgx | 8 | [10.1111/myc.13300](https://doi.org/10.1111/myc.13300) | [33963620](https://www.ncbi.nlm.nih.gov/pubmed/33963620) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Yukawa_2006.pdf` | Yukawa E et al., Effect of CYP2C19 genetic polymorphism…, Journal of clinical pharmac… (2006) | pgx | 8 | [10.1111/j.1365-2710.2006.00712.x](https://doi.org/10.1111/j.1365-2710.2006.00712.x) | [16789993](https://www.ncbi.nlm.nih.gov/pubmed/16789993) | metadata signals extractable PGX data (CYP2C19, PK/PD-context) |
| `Magnusson_2006.pdf` | Magnusson MO et al., A mechanism-based integrated pharmacoki…, Pharmaceutical research (2006) | pgx | 7 | [10.1007/s11095-005-9571-z](https://doi.org/10.1007/s11095-005-9571-z) | [16525862](https://www.ncbi.nlm.nih.gov/pubmed/16525862) | metadata signals extractable PGX data (CYP1A2, PK/PD-context) |
| `Manis_2023.pdf` | Manis MM et al., Managing the Drug-Drug Interaction With…, Hospital pharmacy (2023) | pgx | 7 | [10.1177/00185787221150928](https://doi.org/10.1177/00185787221150928) | [37360203](https://www.ncbi.nlm.nih.gov/pubmed/37360203) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Reidenberg_1995.pdf` | Reidenberg P et al., Effects of felbamate on the pharmacokin…, Clinical pharmacology and t… (1995) | pgx | 7 | [10.1016/0009-9236(95)90244-9](https://doi.org/10.1016/0009-9236(95)90244-9) | [7554701](https://www.ncbi.nlm.nih.gov/pubmed/7554701) | metadata signals extractable PGX data (CYP2C19, PK/PD-context) |
| `Tolbert_2016.pdf` | Tolbert D et al., Drug-metabolism mechanism: Knowledge-ba…, Journal of clinical pharmac… (2016) | pgx | 7 | [10.1002/jcph.603](https://doi.org/10.1002/jcph.603) | [26224203](https://www.ncbi.nlm.nih.gov/pubmed/26224203) | metadata signals extractable PGX data (CYP3A, PK/PD-context) |
| `Walzer_2012.pdf` | Walzer M et al., Pharmacokinetic drug interactions betwe…, Pharmacotherapy (2012) | pgx | 7 | [10.1002/j.1875-9114.2012.01028.x](https://doi.org/10.1002/j.1875-9114.2012.01028.x) | [22422635](https://www.ncbi.nlm.nih.gov/pubmed/22422635) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Wiemann_2023.pdf` | Wiemann C et al., Boscalid shows increased thyroxin-glucu…, Journal of applied toxicolo… (2023) | pgx | 7 | [10.1002/jat.4427](https://doi.org/10.1002/jat.4427) | [36549901](https://www.ncbi.nlm.nih.gov/pubmed/36549901) | metadata signals extractable PGX data (CYP1A, PK/PD-context) |
| `Chiddarwar_2017.pdf` | Chiddarwar AS et al., Genetic Variations in Bilirubin Metabol…, Annals of human genetics (2017) | pgx | 5 | [10.1111/ahg.12179](https://doi.org/10.1111/ahg.12179) | [27943244](https://www.ncbi.nlm.nih.gov/pubmed/27943244) | metadata signals extractable PGX data (UGT1A1) |

<sub>queue written 2026-09-10T01:51:34.057440+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| PGx | Abdul_2021 | not_relevant | 2 | 5 | The paper reports a clinical case of Crigler-Najjar syndrome where phenobarbital was used to lower bilirubin levels, but it does not report a pharmacogenomic study linking a specific genotype to a change in phenobarbital's PK or PD parameters. |
| PGx | Acikgöz_2009 | not_relevant | 0 | 0 | The paper studies the effect of phenobarbital as an enzyme inducer on diazepam metabolism in hepatocytes, not the effect of a gene variant on phenobarbital's PK/PD. |
| PGx | Almond_2016 | not_relevant | 0 | 0 | The paper focuses on predicting drug-drug interactions via CYP3A induction using PBPK models and does not report pharmacogenomic effects (gene variants) on phenobarbital PK/PD. |
| popPK | Asai_2017 | irrelevant | 0 | 0 | The study focuses on the in-vitro metabolism of beta-estradiol by UGT enzymes, using phenobarbital only as an enzyme inducer rather than as the subject drug for pharmacokinetic analysis. |
| PD | Asai_2017 | not_relevant | 0 | 0 | The paper characterizes the metabolism of beta-estradiol in rat brain; phenobarbital is only mentioned as an inducer that did not significantly affect the reaction, with no exposure-response or dose-response PD analysis for phenobarbital itself. |
| PGx | Bai_2021 | not_relevant | 0 | 0 | The paper reports a clinical case of UGT1A1 mutations causing kernicterus and notes that phenobarbital treatment was beneficial, but it does not report a pharmacogenomic study quantifying how specific genotypes alter the pharmacokinetic or pharmacodynamic parameters of phenobarbital. |
| PGx | Breznock_1975 | not_relevant | 0 | 0 | The paper reports a drug-drug interaction (phenobarbital inducing digoxin metabolism) in dogs, not a pharmacogenomic effect based on genetic variants. |
| PGx | Burns_2016 | not_relevant | 0 | 0 | The paper focuses on the pharmacokinetics of clobazam, not phenobarbital, and phenobarbital is only mentioned as a comedication affecting clobazam levels. |
| PGx | Chiddarwar_2017 | not_relevant | 0 | 0 | The study investigates genetic variants associated with hyperbilirubinemia and mentions a phenobarbital-responsive enhancer module, but it does not report pharmacokinetic or pharmacodynamic parameters of phenobarbital itself. |
| PGx | Cokley_2022 | not_relevant | 0 | 0 | The paper discusses drug-drug interactions between Paxlovid and phenobarbital, not pharmacogenomic effects of gene variants on phenobarbital PK/PD. |
| PGx | Cozzi_2022 | not_relevant | 0 | 0 | The paper describes a UGT1A1 variant causing hyperbilirubinemia and its response to phenobarbital, but does not report pharmacokinetic or pharmacodynamic parameters of phenobarbital itself. |
| PGx | Cribb_1995 | not_relevant | 0 | 0 | The paper investigates the metabolism of sulfamethoxazole and the effect of phenobarbital as an enzyme inducer, rather than the pharmacokinetics or pharmacodynamics of phenobarbital itself. |
| PGx | Dashti_2024 | not_relevant | 0 | 0 | The paper reports HLA-B allele frequencies and their associations with adverse drug reactions (hypersensitivity), not pharmacokinetic or pharmacodynamic parameters. |
| popPK | Deshpande_2007 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of endocannabinoids in neuronal cultures where phenobarbital is used only as a comparator agent, with no pharmacokinetic parameters reported. |
| PD | Deshpande_2007 | not_relevant | 0 | 0 | The paper reports dose-response parameters (EC50) for endocannabinoids (methanandamide and 2-AG), not for phenobarbital, which is only mentioned as a refractory control agent. |
| popPK | Dingemanse_1989 | relevant | 10 | 0 | The title confirms a pharmacokinetic modeling study of phenobarbital in rats, but the provided evidence contains no numeric parameter values. |
| PD | Dingemanse_1989 | not_relevant | 0 | 0 | The provided text is only the title of the paper and does not contain the full text, abstract, or results necessary to determine if numeric PD parameters or exposure-response relationships are reported. |
| PGx | Dubey_2003 | not_relevant | 0 | 0 | The paper uses phenobarbital as a CYP450 inducer to study estradiol metabolism in smooth muscle cells, rather than reporting a pharmacogenomic effect on phenobarbital's own PK or PD parameters. |
| popPK | Falcão_2012 | irrelevant | 0 | 0 | The study focuses on eslicarbazepine acetate, not phenobarbital. |
| PD | Falcão_2012 | not_relevant | 0 | 0 | The paper focuses on eslicarbazepine acetate, not phenobarbital. |
| PGx | Foti_2008 | not_relevant | 0 | 0 | The paper focuses on the metabolism and drug-drug interactions of usnic acid, mentioning phenobarbital only as a positive control for enzyme induction, and does not report pharmacogenomic effects on phenobarbital PK/PD. |
| PGx | Hagos_2019 | not_relevant | 0 | 0 | The study focuses on the pharmacokinetics of fentanyl, not phenobarbital, and phenobarbital is only mentioned as a concomitant inducer. |
| PGx | Hall_1987 | not_relevant | 0 | 0 | The paper focuses on the metabolism of mephenytoin and does not report pharmacogenomic effects on the PK or PD parameters of phenobarbital. |
| PGx | Hedrich_2016 | not_relevant | 0 | 0 | The paper is a review of CYP2B6-mediated drug-drug interactions and does not report pharmacogenomic effects on the PK/PD of phenobarbital. |
| PGx | Iba_1995 | not_relevant | 0 | 0 | The paper studies the effects of 3,3-dichlorobenzidine on gene expression and enzyme activity, using phenobarbital only as a negative control, and does not report pharmacogenomic effects on phenobarbital PK/PD. |
| PGx | Kanno_2019 | not_relevant | 0 | 0 | The paper investigates the molecular mechanism of CAR transactivation by CCAR1 using reporter assays and does not report pharmacogenomic effects on phenobarbital PK or PD parameters. |
| PGx | Kapelyukh_2025 | not_relevant | 0 | 0 | The paper investigates drug-drug interactions involving a peptide (NN1177) and does not report pharmacogenomic effects of gene variants on phenobarbital PK/PD. |
| PGx | Lee_2012 | not_relevant | 0 | 0 | The study explicitly reports no significant difference in pharmacokinetic parameters among CYP2C19 genotype groups. |
| popPK | Lee_2019 | irrelevant | 0 | 0 | The study is a pharmacodynamic analysis of respiratory rate and ETCO2, not a pharmacokinetic study of phenobarbital, which is only mentioned as a covariate for antiepileptic drug use. |
| popPK | Leppik_1979 | irrelevant | 2 | 0 | The study focuses on anticonvulsant action and brain content/plasma binding rather than reporting quantitative population pharmacokinetic parameters (CL, V, ka) for phenobarbital. |
| PD | Leppik_1979 | not_relevant | 0 | 0 | The paper focuses on pharmacokinetics (brain content, plasma binding) and qualitative anticonvulsant action, without reporting quantitative exposure-response or dose-response PD parameters for phenobarbital. |
| PGx | Li_2020 | not_relevant | 0 | 0 | The paper reviews drug-drug interactions involving phenobarbital but does not report pharmacogenomic effects (gene variants) on PK/PD parameters. |
| PGx | Magnusson_2006 | not_relevant | 0 | 0 | The study investigates phenobarbital-mediated enzyme induction in rats using a mechanistic PK model, but it does not report any pharmacogenomic effects (gene variants/genotypes) on PK or PD parameters. |
| PGx | Majid_2016 | not_relevant | 0 | 0 | The paper reports the impact of perampanel (a drug) on the pharmacokinetics of phenobarbital, not the impact of a gene variant/genotype on phenobarbital pharmacokinetics. |
| PGx | Manis_2023 | not_relevant | 0 | 0 | The paper describes a drug-drug interaction between primidone and apixaban, not a pharmacogenomic effect on phenobarbital. |
| PGx | Marx-Stoelting_2017 | not_relevant | 0 | 0 | The paper uses phenobarbital as a reference compound to study the hepatotoxicity of fungicides, not to report pharmacogenomic effects on phenobarbital's PK/PD parameters. |
| PGx | McIntyre_1986 | not_relevant | 2 | 5 | The study reports a genetic difference in pharmacodynamic response (sedation/hypnotic effect) but does not provide quantitative fitted effect sizes or specific PK/PD parameter values. |
| PGx | McNary_2025 | not_relevant | 0 | 0 | The study investigates clinical outcomes (thromboembolism, mortality) of drug-drug interactions, not pharmacogenomic effects on PK/PD parameters. |
| PGx | Meirinho_2022 | not_relevant | 0 | 0 | The study investigates drug-drug interactions involving phenobarbital as an inducer, not the effect of a gene variant on phenobarbital's PK/PD. |
| PGx | Menard_2000 | not_relevant | 0 | 0 | The paper studies the metabolism of cicletanine, not phenobarbital, and phenobarbital is only used as an inducing agent in the experimental setup. |
| popPK | Methaneethorn_2021 | irrelevant | 2 | 2 | The paper is a systematic review summarizing ranges from other studies rather than reporting original quantitative disposition parameters from a primary pharmacokinetic study. |
| popPK | Moffett_2018 | relevant | 10 | 2 | The paper is a population PK study for phenobarbital, but the specific numeric parameter values (CL, V, Q, etc.) are not present in the provided text, which only describes the model structure and covariates. |
| PGx | Mori_1995 | not_relevant | 0 | 0 | The paper investigates the effect of cigarette smoke on the metabolic activation of carcinogens in hamsters, using phenobarbital only as a standard enzyme inducer for comparison, and does not report pharmacogenomic effects on phenobarbital's PK or PD. |
| PGx | Murphy_2003 | not_relevant | 0 | 0 | The paper reports a drug-drug interaction between phenytoin and diazepam, not a pharmacogenomic effect on phenobarbital. |
| PGx | Nerurkar_1993 | not_relevant | 0 | 0 | The paper investigates the metabolic specificity of probe substrates (MTR, BZR) for CYP isozymes in rodents and does not report pharmacogenomic effects on phenobarbital PK/PD parameters. |
| PGx | Nessler_2020 | not_relevant | 0 | 0 | The paper describes a genetic variant (PCK2) causing a neurological disorder in dogs and notes that phenobarbital treatment was ineffective, but it does not report a pharmacogenomic effect on phenobarbital's PK or PD parameters. |
| PGx | Okada_2008 | not_relevant | 0 | 0 | The paper investigates the pharmacogenomics of zonisamide, not phenobarbital. |
| PGx | Perucca_2008 | not_relevant | 0 | 0 | The paper discusses drug-drug interactions involving phenobarbital but does not report any pharmacogenomic effects (gene variants) on its PK or PD parameters. |
| PGx | Reidenberg_1995 | not_relevant | 0 | 0 | The study investigates a drug-drug interaction (felbamate) rather than a pharmacogenomic effect (gene variant/genotype). |
| PGx | Reik_1985 | not_relevant | 0 | 0 | The paper focuses on the immunological characterization of cytochrome P-450 isozymes and does not report pharmacogenomic effects of gene variants on phenobarbital PK or PD parameters. |
| PGx | Rost_1994 | not_relevant | 0 | 0 | The paper investigates omeprazole-induced CYP1A2 activity using caffeine as a probe, not the pharmacokinetics or pharmacodynamics of phenobarbital. |
| popPK | Ryu_2021 | irrelevant | 2 | 0 | The paper is an external evaluation of existing models and does not report original quantitative PK parameter estimates (CL, V, etc.) for phenobarbital in the provided evidence. |
| PGx | Saruwatari_2010 | not_relevant | 5 | 0 | The paper is a review that mentions CYP2C9/2C19 effects on phenobarbital PK but does not provide specific quantitative effect sizes or fitted parameters for phenobarbital in the provided text. |
| PGx | Saruwatari_2014 | not_relevant | 0 | 0 | The paper reports pharmacogenomic effects on the pharmacokinetics of clobazam, not phenobarbital. |
| popPK | Schoemaker_2016 | irrelevant | 0 | 0 | The paper focuses on brivaracetam, not phenobarbital, and contains no phenobarbital PK parameters. |
| PD | Schoemaker_2016 | not_relevant | 0 | 0 | The paper focuses on brivaracetam, not phenobarbital, and does not report PD parameters for the specified drug. |
| PGx | Schutzman_2017 | not_relevant | 0 | 0 | The study investigates genetic variants of bilirubin metabolism enzymes (UGT1A1, SLCO1B1) and their effect on hyperbilirubinemia, not the pharmacokinetics or pharmacodynamics of phenobarbital. |
| popPK | Shareef_2018 | relevant | 10 | 2 | The paper describes a population PK study for phenobarbital, but the specific quantitative parameter values (CL, V, etc.) are not present in the provided text, which only offers dosing recommendations and qualitative findings. |
| popPK | Sharpe_2024 | irrelevant | 0 | 0 | The study focuses on the pharmacokinetics of levetiracetam, with phenobarbital serving only as a comparator or second-line treatment without reported PK parameters. |
| PGx | Shimura_2019 | not_relevant | 2 | 5 | The paper reports a pharmacodynamic adverse effect (psychosis) associated with a gene variant, but does not quantify a change in a standard PK/PD parameter (e.g., AUC, Cmax, ED50) of phenobarbital itself. |
| PGx | Sidhu_1995 | not_relevant | 0 | 0 | The paper investigates the modulation of CYP450 gene expression by dexamethasone in rat hepatocytes, not the effect of a human gene variant on the pharmacokinetics or pharmacodynamics of phenobarbital. |
| PGx | Sonnichsen_1995 | not_relevant | 0 | 0 | The paper focuses on paclitaxel metabolism and only mentions phenobarbital as a confounding exposure factor in liver donors, not as the drug of interest for pharmacogenomic analysis. |
| popPK | Stijnen_1992 | irrelevant | 2 | 0 | The study focuses on pharmacodynamic changes (anesthetic threshold/brain sensitivity) with aging rather than reporting quantitative pharmacokinetic disposition parameters (CL, V, etc.) for phenobarbital. |
| PGx | Sueyoshi_2025 | not_relevant | 0 | 0 | The paper is a review of the molecular mechanisms of phenobarbital induction via the CAR receptor and does not report pharmacogenomic effects of gene variants on PK/PD parameters. |
| PGx | Suvichapanich_2015 | not_relevant | 0 | 0 | The study investigates the association between CYP2C9*3 and severe cutaneous adverse reactions (SCARs), not the effect on pharmacokinetic or pharmacodynamic parameters of phenobarbital. |
| popPK | Teixeira-da-Silva_2022 | irrelevant | 0 | 0 | The study focuses on the pharmacokinetics of valproic acid (VPA), with phenobarbital serving only as a comedication covariate affecting VPA clearance. |
| popPK | Todorovic_1998 | irrelevant | 0 | 0 | The study is an in-vitro electrophysiology paper measuring channel block (EC50) and does not report pharmacokinetic parameters for phenobarbital. |
| PGx | Tolbert_2016 | not_relevant | 0 | 0 | The paper investigates drug-drug interactions (DDIs) involving clobazam and phenobarbital, not the pharmacogenomic effects of gene variants on phenobarbital's PK/PD. |
| PGx | Unterberger_2014 | not_relevant | 0 | 0 | The paper investigates the molecular mechanisms of liver tumor formation in a mouse model where phenobarbital is used as a promoter, but it does not report pharmacogenomic effects on phenobarbital's pharmacokinetic or pharmacodynamic parameters. |
| PGx | Van_2021 | not_relevant | 0 | 0 | The paper reports pharmacogenomic effects on the PK of isavuconazole, not phenobarbital. |
| PGx | Voznesensky_1994 | not_relevant | 0 | 0 | The paper investigates electrostatic interactions between P450 reductase and P450 enzymes, mentioning phenobarbital only as an inducer of microsomes, but does not report any pharmacogenomic effects on phenobarbital PK/PD. |
| PGx | Walzer_2012 | not_relevant | 0 | 0 | The paper investigates drug-drug interactions involving clobazam and phenobarbital, not the effect of a gene variant on phenobarbital pharmacokinetics. |
| PGx | Wiemann_2023 | not_relevant | 0 | 0 | The paper studies the effect of boscalid on thyroid hormone metabolism and uses phenobarbital only as a reference inducer, not as the drug of interest for pharmacogenomic analysis. |
| PGx | Wolff_1992 | not_relevant | 0 | 0 | The paper studies the effect of phenobarbital as an enzyme inducer on CYP450 activity, not the pharmacokinetics or pharmacodynamics of phenobarbital itself. |
| popPK | Yalcin_2022 | irrelevant | 2 | 0 | The paper is a literature review that discusses phenobarbital PK in neonates on ECMO but does not report original quantitative parameter values (CL, V, etc.) for phenobarbital in the provided text. |
| popPK | Yang_2024 | irrelevant | 0 | 0 | The provided evidence contains only a title and no quantitative pharmacokinetic parameters or data for phenobarbital. |
| PD | Yang_2024 | not_relevant | 0 | 0 | The paper describes a methodological framework (SSA-1DCNN-Attention) for PK/PD modeling but does not report specific numeric PD parameters or exposure-response relationships for phenobarbital. |
| PGx | Yuan_2017 | not_relevant | 0 | 0 | The paper describes a case of Gilbert syndrome (UGT1A1 mutation) where phenobarbital was used as a treatment, but it does not report how the genotype affects the pharmacokinetics or pharmacodynamics of phenobarbital itself. |
| PGx | Yueh_2007 | not_relevant | 0 | 0 | The paper investigates the regulation of UGT1A1 expression by the Nrf2-Keap1 pathway and mentions the phenobarbital-response enhancer region, but it does not report a pharmacogenomic effect of a gene variant on the PK or PD of phenobarbital. |
| PGx | Zhang_2003 | not_relevant | 0 | 0 | The paper characterizes CYP450 expression and induction by phenobarbital in mice, but does not report how a gene variant affects the PK or PD of phenobarbital. |
| PGx | Zhu_2022 | not_relevant | 0 | 0 | The paper focuses on the pharmacokinetics of valproic acid, not phenobarbital. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-09-10 01:52 UTC</sub>
